Compare Adaptive Biotechnologies Corp (ADPT) vs iShares MSCI Canada (TSX) (EWC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares MSCI Canada (TSX) — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while iShares MSCI Canada (TSX) trades at $57.89. Which is the better fit depends on your goals.
| ADPT | EWC | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $22.37 | $59.46 |
52-Week Low | $10.24 | $45.86 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
EWC trades at $58.06, up 0.5% with a bullish technical signal supported by moving averages. The stock shows neutral oscillator readings with RSI at 78.59 indicating potential overbought conditions. Recent news highlights Canada's widening trade surplus and economic policy developments, which may impact this Canada-focused ETF. A dividend of $0.28 is scheduled for June 2026.
Outlook remains cautiously optimistic given bullish technicals and positive economic indicators from Canada, though overbought RSI suggests near-term consolidation. Risks include trade policy uncertainty and macroeconomic shifts. Investors should weigh technical strength against valuation metrics pending further fundamental data.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →
